Business Context and Reporting Period
Aclarion, Inc. (ACON), an emerging growth company incorporated in Delaware, filed this Form 8-K on January 31, 2025, reporting events occurring on January 30, 2025. The company is headquartered in Broomfield, Colorado, and its common stock and warrants trade on the Nasdaq Stock Market.
Key Financial Metrics and Transaction Details
This filing details a registered direct offering rather than periodic financial results. Key transaction metrics include:
- Shares Issued: 506,803 shares of common stock.
- Price Per Share: $9.25.
- Gross Proceeds: Approximately $4.7 million.
- Placement Agent Fee: 7% of aggregate gross proceeds paid to Dawson James Securities, Inc.
- Use of Proceeds: Market development, clinical evidence, product development, quality assurance, general and administrative support, and other corporate purposes.
The filing does not provide current revenue, profit, cash flow, margin, or debt figures.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement and a Placement Agency Agreement to raise capital. This transaction increases the company's share count and cash liquidity pending the closing of the offering, expected on or about January 31, 2025.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance clinical evidence and product development. The offering is subject to customary closing conditions. The filing notes that the press release furnished as Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and offering expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any specific covenants or restrictions.
- Confirm the updated share count and potential dilution impact on existing shareholders.
- Monitor subsequent filings for the actual deployment of funds toward clinical evidence and product development milestones.